Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review.

IF 6.1 2区生物学 Q1 CELL BIOLOGY

Cell Death Discovery Pub Date : 2025-07-24 DOI:10.1038/s41420-025-02566-x

Hideyuki Masuda

引用次数: 0

Abstract

Although cancer treatment saves many lives, some types of cancer, such as pancreatic ductal adenocarcinoma (PDAC), exhibit therapeutic resistance and continue to show high mortality. Tumors in cancers such as PDAC contain a substantial amount of cancer-associated fibroblast (CAF)-secreted collagen and other extracellular matrix (ECM) components, which significantly contribute to cancer therapeutic resistance. In the tumor microenvironment, CAFs stabilize the tissue by producing ECM components, remodel ECM through degradation, induce metastasis through epithelial-mesenchymal transition, and suppress cancer immune responses. Recent advances in single-cell analysis have gradually elucidated the subtypes of CAFs and their functions, leading to the emergence of CAF-targeting therapeutic strategies. In this review, I provide an overview of CAFs, their functions and classifications, the mechanisms underlying their role in therapeutic resistance, and the current status of CAF-targeting therapeutic strategies. Moreover, I explored how we can advance cancer treatment by leveraging our understanding of CAFs.

查看原文本刊更多论文

癌症相关成纤维细胞在癌症耐药和癌症进展中的研究进展

尽管癌症治疗挽救了许多生命，但某些类型的癌症，如胰腺导管腺癌（PDAC），表现出治疗耐药性，并继续显示出高死亡率。PDAC等癌症肿瘤中含有大量的癌症相关成纤维细胞（CAF）分泌的胶原蛋白和其他细胞外基质（ECM）成分，这些成分对癌症治疗耐药性有重要作用。在肿瘤微环境中，CAFs通过产生ECM成分来稳定组织，通过降解重塑ECM，通过上皮-间质转化诱导转移，抑制肿瘤免疫反应。单细胞分析的最新进展逐渐阐明了CAFs的亚型及其功能，从而导致了针对CAFs的治疗策略的出现。在本文中，我综述了CAFs，其功能和分类，其在治疗耐药中的作用机制，以及CAFs靶向治疗策略的现状。此外，我还探讨了如何利用我们对caf的理解来推进癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Death Discovery Biochemistry, Genetics and Molecular Biology-Cell Biology

CiteScore

8.30

自引率

1.40%

发文量

468

审稿时长

9 weeks

期刊介绍： Cell Death Discovery is a multidisciplinary, international, online-only, open access journal, dedicated to publishing research at the intersection of medicine with biochemistry, pharmacology, immunology, cell biology and cell death, provided it is scientifically sound. The unrestricted access to research findings in Cell Death Discovery will foster a dynamic and highly productive dialogue between basic scientists and clinicians, as well as researchers in industry with a focus on cancer, neurobiology and inflammation research. As an official journal of the Cell Death Differentiation Association (ADMC), Cell Death Discovery will build upon the success of Cell Death & Differentiation and Cell Death & Disease in publishing important peer-reviewed original research, timely reviews and editorial commentary. Cell Death Discovery is committed to increasing the reproducibility of research. To this end, in conjunction with its sister journals Cell Death & Differentiation and Cell Death & Disease, Cell Death Discovery provides a unique forum for scientists as well as clinicians and members of the pharmaceutical and biotechnical industry. It is committed to the rapid publication of high quality original papers that relate to these subjects, together with topical, usually solicited, reviews, editorial correspondence and occasional commentaries on controversial and scientifically informative issues.